RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2022)

RedHill Biopharma (RDHL) has 3 years of Non-Current Debt data on file, last reported at $115.2 million in Q4 2022.

• On a quarterly basis, Non-Current Debt rose 37.79% year-over-year to $115.2 million in Q4 2022; TTM through Dec 2022 was $115.2 million, a 37.79% increase from a year earlier, with the FY2022 full-year figure at $115.2 million, up 37.79% from the prior year.
• Non-Current Debt for Q4 2022 stood at $115.2 million, up from $113.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for RDHL reached as high as $115.2 million in Q4 2022 and fell as low as $78.2 million in Q1 2020.
• Historically, Non-Current Debt has averaged $87.7 million across 3 years, with a median of $83.3 million in 2021.
• Across the five-year window, Non-Current Debt advanced 2.74% in 2021 and soared 37.79% in 2022, its largest moves.
• Year by year, Non-Current Debt stood at $81.4 million in 2020, then increased by 2.74% to $83.6 million in 2021, then jumped by 37.79% to $115.2 million in 2022.
• Per Business Quant data, the three most recent Non-Current Debt figures were $115.2 million in Q4 2022, $113.9 million in Q3 2022, and $85.5 million in Q2 2022.